147080-28-2

Usage

Uses

Used in Pharmaceutical Research:
5-(methylthio)indoline is utilized as a key intermediate in the synthesis of various pharmaceutical compounds, leveraging its unique chemical structure to contribute to the development of new drugs.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-(methylthio)indoline is employed for the creation of complex organic molecules, facilitating the advancement of chemical research and the discovery of novel compounds with diverse applications.
Used in Anticancer Applications:
5-(methylthio)indoline is studied for its potential as an anti-cancer agent, where it may contribute to the inhibition of tumor growth and the modulation of oncological signaling pathways, offering a promising avenue for cancer treatment.
Used in Bacterial Inhibition:
5-(methylthio)indoline is recognized for its ability to inhibit the growth of certain bacteria, making it a candidate for use in antimicrobial applications and potentially contributing to the development of new antibiotics.
Used in Fluorescent Dye Applications:
Known for its potential as a fluorescent dye, 5-(methylthio)indoline is employed in imaging and sensing applications, where its optical properties can be harnessed for various analytical techniques and diagnostic tools.
Used in Imaging and Sensing Applications:
5-(methylthio)indoline's fluorescent properties are leveraged in the development of imaging agents and sensing technologies, enhancing the capabilities of these fields through improved detection and visualization methods.

Upstream product

• 162100-46-1 1-(5-Methylsulfanyl-2,3-dihydro-indol-1-yl)-ethanone 
• 77248-65-8 5-methylthio-1H-indole 
• 496-15-1 1-indoline 
• 74-88-4 methyl iodide 
• 162100-36-9 1-(5-Mercapto-2,3-dihydro-indol-1-yl)-ethanone 

Downstream Products

• 387350-92-7 5-(methylsulfonyl)-2,3-dihydro-1H-indole 

Relevant academic research and scientific papers

Optimization of a novel series of potent and orally bioavailable GPR119 agonists

We describe the discovery and optimization of a novel series of furo[3,2-d]pyrimidines as G protein-coupled receptor 119 agonists. Agonistic activity of 4 (EC50?=?129?nM) was improved by replacing the intramolecular hydrogen bond between the fluorine atom and the aniline hydrogen in the head moiety with a covalent C-C bond to enhance conformational restriction, which consequently gave a lead compound 12 (EC50?=?53?nM). Optimized compound 26, which was identified by the further optimization of 12, exhibited potent activity (EC50?=?42?nM) with improved clearance in liver microsomes and induced a 33% reduction in blood glucose area under the curve at a dose of 10?mg/kg in an oral glucose tolerance test in C57BL/6N mice.

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure-activity relationships

Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 7b. Their related synthesis was also reported.

Novel and selective 5-HT(2C/2B) receptor antagonists as potential anxiolytic agents: Synthesis, quantitative structure - Activity relationships, and molecular modeling of substituted 1-(3- pyridylcarbamoyl)indolines

The synthesis, biological activity, and molecular modeling of a novel series of substituted 1-(3-pyridylcarbamoyl)indolines are reported. These compounds are isosteres of the previously published indole urea 1 (SB- 206553) and illustrate the use of aromatic disubstitution as a replacement for fused five-membered rings in the context of 5-HT(2C/2B) receptor antagonists. By targeting a region of space previously identified as sterically allowed at the 5-HT(2C) receptor but disallowed at the 5-HT(2A) receptor, we have identified a number of compounds which are the most potent and selective 5-HT(2C/2B) receptor antagonists yet reported. 46 (SB-221284) was selected on the basis of its overall biological profile for further evaluation as a novel, potential nonsedating anxiolytic agent. A CoMFA analysis of these compounds produced a model with good predictive value and in addition good qualitative agreement with both our 5-HT(2C) receptor model and our proposed binding mode for this class of ligands within that model.